Free CPJE Exam Flashcards

A valid Rx must show patient name, drug name/strength/quantity, directions for use, prescriber name and signature (or a DEA-compliant e-Rx equivalent), and the date issued. Missing or altered elements make the Rx invalid to fill until corrected with the prescriber.

The profile (allergies, disease states, current drug therapy) lets the pharmacist perform prospective drug utilization review - screening new orders for interactions, duplications, and contraindications - before the drug reaches the patient.

The pharmacist must contact the prescriber to clarify before filling. Dispensing based on a guess violates the duty to verify a prescription's accuracy and authenticity, a core Patient Info & Rx Evaluation competency.

A prescription is issued by a prescriber for an outpatient to be filled at a pharmacy. A medication order is issued for a patient in a licensed healthcare facility (e.g., hospital) and is administered by facility staff, not dispensed directly to the patient.

No. Schedule II prescriptions must be written or transmitted as a compliant electronic prescription. Verbal orders are allowed only in a bona fide emergency, and the prescriber must furnish a written or electronic follow-up promptly.

Within 6 months of the date issued. After that window, the prescription expires and cannot be dispensed even if the prescriber's signature and other elements remain valid.

Schedule III-V orders may be written, oral, or faxed. Schedule II orders require a written or compliant e-prescription (verbal only for bona fide emergencies) - the extra flexibility for III-V reflects their lower abuse potential.

Electronic prescribing (e-prescribing) became mandatory for controlled substances, with limited statutory exceptions (e.g., technology failure, an out-of-state prescriber). Paper CS scripts outside an exception are noncompliant.

The pharmacist may partial-fill the CII prescription, but must dispense the remaining quantity within 72 hours of the first partial fill (16 CCR 1745; 21 CFR 1306.13(a)). If it can't be completed within 72 hours, the pharmacist notifies the prescriber and the balance can't be dispensed without a new prescription.

Insufficient stock: the remaining quantity must be dispensed within 72 hours of the first partial fill (16 CCR 1745). A patient- or prescriber-requested partial fill may be completed within 30 days of the date written (21 CFR 1306.13(b); B&P 4052.10). An emergency oral CII order is separate - the prescriber must deliver a written follow-up within 7 days.

Generally no - a one-time transfer is allowed between pharmacies that don't share a real-time online database. Pharmacies sharing such a database may transfer remaining refills multiple times up to the prescription's authorized limit. Schedule II prescriptions are not transferable at all.

When the prescriber is unavailable to authorize a refill and, in the pharmacist's professional judgment, failure to refill would interrupt the patient's ongoing therapy in a way that could harm the patient. The pharmacist must attempt to contact the prescriber, document the emergency dispensing, and notify the prescriber afterward.

Schedule II. The emergency-refill authority under section 4064 covers dangerous drugs and Schedule III-V controlled substances only - Schedule II drugs can never be refilled this way because Schedule II prescriptions have no refills at all.

SB 472 created the standardized, patient-centered prescription label format, requiring consistent placement of the drug name, strength, directions, and prescriber information so patients can more easily read and compare their labels across pharmacies.

California requires interpreter services during pharmacy hours and translated prescription directions (SIG) in the state's top languages (Spanish, Chinese, Korean, Russian, Vietnamese) upon request, to ensure LEP patients understand how to take their medication safely.

Schedule I substances (e.g., heroin, LSD) have no accepted medical use and a high potential for abuse under the CSA. Because there is no legitimate prescribing use, a pharmacist cannot lawfully fill a prescription for one in routine practice.

They are Schedule III - moderate abuse potential. Schedule III-V prescriptions may authorize up to 5 refills within 6 months of the issue date, unlike Schedule II, which permits no refills.

They are Schedule IV - low abuse potential relative to Schedule II drugs like oxycodone or Adderall (high abuse potential, tightly restricted refills and format). Schedule IV allows refills and more flexible prescription formats.

Yes. Under a statewide standing protocol, pharmacists may furnish naloxone directly to patients, family members, or others in a position to assist someone at risk of opioid overdose - no individual prescription is required.

After the pharmacist completes a self-screening questionnaire with the patient to check for contraindications. The pharmacist then furnishes the contraceptive directly and must notify the patient's primary care provider or give the patient a record of the encounter.

PrEP (pre-exposure prophylaxis) furnishing authority comes from B&P 4052.02; PEP (post-exposure prophylaxis, for after a suspected HIV exposure) comes from B&P 4052.03. Both are protocol-based and don't require an individual physician prescription.

No. Pharmacists may furnish CDC-recommended travel medications based on the destination and traveler's needs without a prior physician diagnosis, alongside their other furnishing authority for naloxone, contraceptives, PrEP/PEP, and nicotine replacement therapy.

It means the pharmacist shares legal responsibility with the prescriber for ensuring a controlled substance prescription was issued for a legitimate medical purpose - a pharmacist cannot simply fill an order and blame the prescriber if red flags were ignored.

Cash payment for a controlled substance (avoiding an insurance paper trail) and a long distance between the patient's home, the prescriber, and the pharmacy (suggesting doctor- or pharmacy-shopping) are classic corresponding-responsibility red flags requiring further verification.

This is a 'doctor-shopping' red flag suggesting possible diversion or addiction. The pharmacist must investigate (e.g., check CURES under corresponding responsibility) and may refuse to fill, documenting the reasoning, rather than dispense without resolving the concern.

16 CCR 1707.2 requires the pharmacist to proactively provide oral consultation to the patient (or caregiver) for a new prescription or a change in directions/strength - it is not satisfied by merely offering and letting the patient decline unprompted.

A new drug for the patient, or a change in strength or directions for an existing drug. Refills with no change in therapy do not automatically trigger a new mandatory consultation, though the patient may still request one.

The pharmacy must provide written notice of the right to counseling plus telephone access to a pharmacist, and the patient may decline consultation (documented as a refusal) - the patient's right to opt out is preserved even remotely.

OBRA '90 established mandatory drug utilization review (DUR) and the requirement to offer counseling to Medicaid patients. California's own Duty to Consult (16 CCR 1707.2) goes further by requiring actual consultation, not just an offer.

Only the 'minimum necessary' amount of protected health information needed to accomplish the purpose of the disclosure - pharmacies should not share more patient data than the specific request requires.

Every 3 years. An expired DEA registration means the pharmacist can no longer lawfully dispense controlled substances until it is renewed, regardless of California license status.

California is the only state that develops and administers its own pharmacy jurisprudence exam (CPJE) rather than using NABP's Multistate Pharmacy Jurisprudence Examination (MPJE). The CPJE also uniquely tests clinical practice knowledge, not just law.

California requires an affirmative, proactive consultation for qualifying prescriptions (a stricter standard), while the OBRA '90 model only requires the pharmacist to offer counseling and lets the patient decline - CA's rule leaves less room to skip counseling silently.

13 members total: 7 licensed pharmacists and 6 public members. This mixed composition is designed to balance professional expertise with consumer protection oversight.

It requires the CPJE to test both clinical pharmacy practice and jurisprudence (law) - the reason the CPJE, unlike the MPJE used elsewhere, includes drug-therapy and clinical-judgment questions alongside legal ones.

The prescriber. Pharmacists are not required to query CURES before dispensing; they must register for CURES access and may check it under their corresponding responsibility, but the mandatory pre-prescribing query duty (roughly every 6 months for continuing patients) belongs to prescribers.

CURES (Controlled Substance Utilization Review and Evaluation System) is California's prescription drug monitoring program (PDMP), operated by the California Department of Justice - not the Board of Pharmacy.

Within 2 business days of the error being identified, as part of the pharmacy's mandatory quality assurance program required by 16 CCR 1711.

At least 1 year, and the records must be immediately retrievable - not archived somewhere inaccessible - so the Board can review them during an inspection or investigation.

It's the community/outpatient pharmacy self-assessment form, a periodic self-audit of compliance with pharmacy law and QA standards. Completed self-assessments must be retained on file for 3 years.

Yes - any amount of employee theft must be reported, with no minimum quantity threshold, within 14 days of discovery. This is stricter than the reporting rule for non-theft losses.

Non-theft losses must be reported within 30 days once they meet the reportable threshold - for example, an aggregate of 99 dosage units for tablets. Below that threshold, routine inventory variance isn't independently reportable.

Biennially - every 2 years - as the baseline CS inventory requirement, separate from the theft/loss reporting rules that apply whenever a discrepancy is discovered.

A pharmacy with only one pharmacist on duty may supervise no more than 1 technician (1:1). The 2:1 ratio applies only to each additional pharmacist beyond the first - so 2 pharmacists on duty may supervise up to 3 technicians.

Hospital/inpatient settings commonly use a 1-pharmacist-to-2-technician ratio as well, but the specific ratio can be adjusted based on the facility's approved staffing plan - always subject to the pharmacist's direct supervision requirement.

A technician cannot counsel patients or exercise clinical/professional judgment (e.g., deciding whether to fill a questionable prescription) - those tasks require direct pharmacist involvement and verification of all technician work.

California requires at least TWO of three criteria (B&P 4210): (1) a board-certified specialty (e.g., BPS), (2) completion of an accredited PGY residency with at least 50% direct patient care, or (3) at least one year of clinical services to patients under a collaborative practice agreement or protocol. APh status also requires a separate application - there is no 1,500-hour figure in the statute.

No. APh status requires meeting at least two of the three defined criteria (certification, residency, or one year of protocol-based clinical services) plus a separate application and fee to the Board - it is never an automatic upgrade from licensure alone.

Every 2 years, with the renewal deadline tied to the pharmacist's birth month - not a fixed calendar date shared by all licensees.

30 total CE hours per renewal cycle, including at least 2 hours of law/ethics and 1 hour of cultural competency - general CE hours alone don't satisfy the mandatory subject-specific minimums.